bioeq GmbH
🇩🇪Germany
Clinical Trials
20
Active:13
Completed:7
Trial Phases
2 Phases
Phase 1:13
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
13 (72.2%)Phase 3
5 (27.8%)A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Bioeq GmbH
- Target Recruit Count
- 392
- Registration Number
- NCT04595409
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: FYB203 (Proposed aflibercept biosimilar)
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Bioeq GmbH
- Target Recruit Count
- 434
- Registration Number
- NCT04522167
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Phase 3
Completed
- Conditions
- Age-related Macular Degeneration (AMD)
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Bioeq GmbH
- Target Recruit Count
- 712
- Registration Number
- NCT02611778
- Locations
- 🇬🇧
Research Site, Rugby, United Kingdom
🇩🇪University of Bonn, Department of Ophthalmology, Bonn, Germany
News
No news found